16 Dec Cellular Dynamics appoints new commercial, financial executives
Madison, Wis. – Cellular Dynamics International has announced the appointment of three new executives to lead the company as it attempts to industrialize stem cell technologies after raising $18 million in venture capital.
The Madison-based company, which is positioning itself in the pluripotent stem cell industry, named Chris Kendrick-Parker as its chief commercial officer, Emile Nuwaysir as chief operating officer, and David S. Snyder as chief financial officer.
Kendrick-Parker most recently served as vice president of the global pharmaceutical business unit at Affymetrix. His background also includes a stint on the drug discovery services team at Amersham Pharmacia, and as a researcher in molecular and cellular biology in the Department of Human Oncology at the University of Wisconsin-Madison’s Comprehensive Cancer Center.
Nuwaysir will be responsible for CDI’s product development, manufacturing, and quality systems. He has served as senior vice president of program management and business development and CTO of the Roche NimbleGen business unit within Roche Diagnostics, and was a postdoctoral researcher at the National Human Genome Research Institute and the National Institute of Environmental Health Sciences. He helped establish what later became known as the National Center for Toxicogenomics.
Snyder has more than 18 years of experience as a CFO, most recently as site vice president and CFO of the Roche NimbleGen unit in Roche Diagnostics. He had joined Roche NimbleGen to lead the company’s IPO, which led to the sale of NimbleGen to Roche for $272.5 million.
CDI recently closed an $18 million financing round and merged with two other stem cell companies founded by UW-Madison stem cell researcher James Thomson.